or Try an Advanced Search...

    Technical Analysis for PYXS - Pyxis Oncology, Inc.

    Grade Last Price % Change Price Change
    D 4.50 -0.66% -0.03
    PYXS closed down 0.66 percent on Tuesday, April 23, 2024, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical PYXS trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -0.66%
    Oversold Stochastic Weakness -0.66%
    Stochastic Reached Oversold Weakness 8.17%
    Wide Bands Range Expansion 8.17%
    Oversold Stochastic Weakness 8.17%
    20 DMA Resistance Bearish -0.66%
    Older End-of-Day Signals for PYXS ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 13 hours ago
    Down 1% about 14 hours ago
    Possible NR7 about 15 hours ago
    Rose Above Previous Day's High about 19 hours ago
    Up 3% about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PYXS Chart by TradingView
    Basic chart:

    Profile

    Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Immunotherapy Cancer Treatment Monoclonal Antibody Acute Myeloid Leukemia Immunotherapies Non Small Cell Lung Cancer Antineoplastic Drugs Small Cell Lung Cancer Antibody Drug Conjugate Treatment Of Acute Myeloid Leukemia Blood Cancers Soft Tissue Sarcoma Treatment Of Non Small Cell Lung Cancer

    Is PYXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 28 Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
    Mar 27 Pyxis Oncology files to sell 10.46M common shares for holders
    Mar 27 Pyxis Oncology gets $8M payment for sale of royalty rights
    Mar 27 Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
    Mar 22 Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Mar 21 Pyxis Oncology GAAP EPS of -$1.85 beats by $0.10
    Mar 21 Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges
    Mar 21 Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
    Mar 13 Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
    Mar 7 Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
    See more PYXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.85
    52 Week Low 1.35
    Average Volume 822,116
    200-Day Moving Average 2.92
    50-Day Moving Average 5.15
    20-Day Moving Average 4.84
    10-Day Moving Average 4.73
    Average True Range 0.53
    RSI (14) 45.05
    ADX 15.12
    +DI 19.59
    -DI 23.18
    Chandelier Exit (Long, 3 ATRs) 4.61
    Chandelier Exit (Short, 3 ATRs) 5.18
    Upper Bollinger Bands 5.83
    Lower Bollinger Band 3.85
    Percent B (%b) 0.33
    BandWidth 41.02
    MACD Line -0.13
    MACD Signal Line -0.06
    MACD Histogram -0.0739
    Fundamentals Value
    Market Cap 199.45 Million
    Num Shares 44.3 Million
    EPS -2.56
    Price-to-Earnings (P/E) Ratio -1.76
    Price-to-Sales 0.00
    Price-to-Book 1.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.93
    Resistance 3 (R3) 4.96 4.84 4.86
    Resistance 2 (R2) 4.84 4.73 4.83 4.84
    Resistance 1 (R1) 4.67 4.66 4.61 4.64 4.81
    Pivot Point 4.55 4.55 4.52 4.54 4.55
    Support 1 (S1) 4.38 4.44 4.32 4.36 4.19
    Support 2 (S2) 4.26 4.37 4.25 4.16
    Support 3 (S3) 4.09 4.26 4.14
    Support 4 (S4) 4.07